<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJOC</journal-id><journal-title-group><journal-title>International Journal of Organic Chemistry</journal-title></journal-title-group><issn pub-type="epub">2161-4687</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijoc.2020.101001</article-id><article-id pub-id-type="publisher-id">IJOC-98707</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Novel Hydralazine Schiff Base Derivatives and Their Antimicrobial, Antioxidant and Antiplasmodial Properties
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Angelbert</surname><given-names>F. Awantu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yannick</surname><given-names>Stephane F. Fongang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Godfred</surname><given-names>A. Ayimele</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Edouard</surname><given-names>A. Nantia</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Patrick</surname><given-names>V. T. Fokou</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fabrice</surname><given-names>F. Boyom</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Celine</surname><given-names>K. Ngwang</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bruno</surname><given-names>N. Lenta</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Silvère</surname><given-names>A. Ngouela</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib></contrib-group><aff id="aff7"><addr-line>Department of Organic Chemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon</addr-line></aff><aff id="aff2"><addr-line>Department of Chemistry, University of Maroua, Maroua, Cameroon</addr-line></aff><aff id="aff1"><addr-line>Department of Chemistry, The University of Bamenda, Bambili, Cameroon</addr-line></aff><aff id="aff5"><addr-line>Department of Biochemistry, University of Yaoundé I, Yaoundé, Cameroon</addr-line></aff><aff id="aff6"><addr-line>Department of Chemistry, Higher Teachers’ Training College, University of Yaoundé I, Yaoundé, Cameroon</addr-line></aff><aff id="aff4"><addr-line>Department of Biochemistry, The University of Bamenda, Bambili, Cameroon</addr-line></aff><aff id="aff3"><addr-line>Department of Chemistry, University of Buea, Buea, Cameroon</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>03</month><year>2020</year></pub-date><volume>10</volume><issue>01</issue><fpage>1</fpage><lpage>16</lpage><history><date date-type="received"><day>27,</day>	<month>January</month>	<year>2020</year></date><date date-type="rev-recd"><day>3,</day>	<month>March</month>	<year>2020</year>	</date><date date-type="accepted"><day>6,</day>	<month>March</month>	<year>2020</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Two novel Schiff bases, 3-[1-(2-(phthalazin-1-yl)hydrazono)ethyl)-1,3-oxa- zinane (PHEO) and 2-[(2-(phthalazin-1-yl)hydrazono)methyl]phenol (PHMP), derived from hydralazine hydrochloride, an effective drug against hypertension, were synthesized and characterized by spectroscopic methods, Infrared (IR), Proton Nuclear Magnetic Resonance (
  <sup>1</sup>H NMR) and Carbon-13 Nuclear Magnetic Resonance (
  <sup>13</sup>C NMR). PHEO showed low antimicrobial activity against one bacterial strain with MIC value of 250 μg/ml while PHMP showed interesting activity against 4 bacterial strains with MIC of 31.25 - 250 μg/ml compared to the standard drug, amoxicillin. PHEO and PHMP showed higher reducing activity on ferric ions compared to Vitamin C. On lipid peroxidation, PHEO showed higher inhibition while PHMP showed lower inhibition compared to Vitamin C. Both compounds presented lower stimulating effect and lower catalase activity compared to the standard Vitamin C. PHEO and PHMP showed less than 80% inhibition in the preliminary antiplasmodial assay and so were not considered for the dose-response studies.
 
</p></abstract><kwd-group><kwd>Hydralazine Hydrochloride</kwd><kwd> Schiff Bases</kwd><kwd> Antimicrobial</kwd><kwd> Anti-Oxidant</kwd><kwd> Anti-Plasmodial Activities</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Health problems have been a source of sadness and pain to humanity and research in the domain of health has afforded a great variety of therapeutics to fight against a wide range of diseases and ailments. Despite this effort and many others, some drugs have become ineffective as the micro organism develops resistance when the usage is recurrent, reason why illnesses like malaria, bacterial and yeast infections, gastrointestinal disorders, diarrhoea, dysentery, cholera, as well as chronic degenerative diseases like cancer, continue to inflict suffering in developing countries, Africa and the world. There is therefore urgent need to discover new drugs.</p><p>Condensation between primary amines and carbonyl compounds affords Schiff bases. The imine (-C=N-) functional group is a versatile pharmacophore for the design and development of biologically active leads. Schiff bases constitute an important class of organic compounds that show a wide variety of applications in many fields including the pharmaceutical and medicinal fields because of the wide range of biological activities they portray including anti-inflammatory [<xref ref-type="bibr" rid="scirp.98707-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref4">4</xref>], antimicrobial [<xref ref-type="bibr" rid="scirp.98707-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref6">6</xref>], antitubercular [<xref ref-type="bibr" rid="scirp.98707-ref7">7</xref>], antioxidant [<xref ref-type="bibr" rid="scirp.98707-ref8">8</xref>], anthelmintic [<xref ref-type="bibr" rid="scirp.98707-ref9">9</xref>], analgesic [<xref ref-type="bibr" rid="scirp.98707-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref10">10</xref>] and anticonvulsant [<xref ref-type="bibr" rid="scirp.98707-ref11">11</xref>] activities among others. Apart from their pharmaceutical and medicinal importance, Schiff bases are widely used as catalysts, dyes, stabilizers in polymer formulations, pigments and corrosion inhibitory agents [<xref ref-type="bibr" rid="scirp.98707-ref12">12</xref>].</p><p>The growing resistance of infectious microorganisms to therapeutics is a serious concern and represents a health threat in both developed and developing world [<xref ref-type="bibr" rid="scirp.98707-ref13">13</xref>]. Introduction of new classes of antimicrobial drugs is desperately needed to hamper the tendency of drugs to quickly develop drug-resistant pathogens [<xref ref-type="bibr" rid="scirp.98707-ref13">13</xref>]. Therefore, drug discovery efforts will facilitate the identification of novel antimicrobial compounds and new drug combinations will facilitate the development of better dosing regimens and novel strategies to manage drug resistance and prevent the dissemination of resistant bacteria [<xref ref-type="bibr" rid="scirp.98707-ref14">14</xref>]. In Cameroon, infectious diseases such as malaria and bacterial infections are amongst the most commonly notified diseases and largest cause of mortality [<xref ref-type="bibr" rid="scirp.98707-ref15">15</xref>]. Malaria continues to be a major cause of childhood mortality and was responsible for an estimated 303,000 (165,000 - 450,000) deaths in children under 5 years old in 2015. The majority is caused by the Plasmodium falciparum infections. However, the 60% reduction observed in mortality since 2000 is heavily associated to the widespread deployment of effective control measures such as Artemisinin-based Combination Therapies (ACTs). The recent emergence and spread of Plasmodium falciparum parasites resistant to ACTs, worsened by the spread of insecticide resistance hindered the elimination of malaria [<xref ref-type="bibr" rid="scirp.98707-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref18">18</xref>].</p><p>An antioxidant is any molecule that delays, prevents or removes oxidative damage to target cells. Oxidative damage or oxidative stress produces free radicals which are dangerous to the body. Reactive oxygen species (ROS) is a term which encompasses all highly reactive molecules including free radicals like hydroxyl radical, superoxide anion radical, hydrogen peroxides, singlet oxygen, nitric acid radical and various peroxides [<xref ref-type="bibr" rid="scirp.98707-ref19">19</xref>]. When oxidative forces exceed the antioxidant systems, the cell is subjected to oxidative stress [<xref ref-type="bibr" rid="scirp.98707-ref19">19</xref>]. Oxidative stress is among the major causative factors in induction of many chronic and degenerative diseases including atherosclerosis, ischemic heart disease, aging, diabetes mellitus, cancer, immunosuppression, neurodegenerative diseases, male infertility, infectious diseases and others [<xref ref-type="bibr" rid="scirp.98707-ref20">20</xref>]. Therefore, development of new antimalarial, antibacterial and antioxidant chemotypes is an urgent priority. Our objective in this study is to synthesize new hydralazine-derived Schiff bases and to evaluate them for their antiplasmodial, antibacterial and antioxidant activity in vitro.</p></sec><sec id="s2"><title>2. Experimental</title><sec id="s2_1"><title>2.1. Materials</title><p>Hydralazine hydrochloride, 4-acetylmorpholine, 2-hydroxybenzaldehyde and other solvents were purchased from commercial sources and used without further purification. All chemicals used were of reagent grade. Methanol was used as solvent all through the synthesis. Glass apparatus with standard interchangeable joint were used after being washed with concentrated sulphuric acid, distilled water and methanol. All the synthesis was carried out in a 250 mL round-bottomed flask fitted with a quick Liebig condenser where it involved refluxing. All reactions were performed on a hot plate equipped with a magnetic stirrer. Elemental analysis was performed on a VARIO EL (Heraeus) analyzer. IR spectra were obtained from a Perkin-Elmer spectrum 100-FT-IR spectrometer. <sup>1</sup>H-NMR spectra were obtained on a Varian unity plus 400 MHz instrument. <sup>13</sup>C-NMR spectra were recorded on a Bruker AV 100 MHz instrument.</p></sec><sec id="s2_2"><title>2.2. Synthesis of 3-[1-(2-(Phthalazin-1-yl)Hydrazono)Ethyl)- 1,3-Oxazinane (PHEO)</title><p>The ligand was prepared by the condensation reaction between hydralazine hydrochloride and 4-Acetylmorpholine. (3 mmol, 0.6 g) of hydralazine hydrochloride and sodium acetate (buffering agent) (3 mmol, 0.4 g) was dissolved in 20 mL of ethanol, and (3 mmol, 0.4 g) of 4-Acetylmorpholine was also measured. The two solutions were transferred into a 250 mL round bottom flask and the mixture was refluxed for three hours while stirring at a temperature of 70˚C and allowed to cool overnight. The yellow precipitate obtained (PHEO) was separated by filtration, washed with ethanol and allowed to air dry giving a yield of 50%. The filtrate was sealed using paraffin in a vial and kept for further crystalization by slow evaporation to improve on the yield. The synthetic route for PHEO is shown in Scheme 1.</p><p>IR (KBr, cm<sup>−1</sup>): ν 3862, 3501, 1271, 1664, 1611, 970. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 500 MHz): 8.85 (s, 1H, N-H), 8.10 (dd, 1H, C-H of benzene ring), 2.45 (s, 3H, H-8’), 2.29 (t, 4H, H-3’, H-4’), 2.60 (t, 4H, H-6’, H-7’) ppm. <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 125 MHz): 151.6 (C-1’), 135.9 (C-1), 134.2 (C-4) ppm.</p><disp-formula id="scirp.98707-formula1"><graphic  xlink:href="//html.scirp.org/file/1-1020713x2.png"  xlink:type="simple"/></disp-formula><p>Scheme 1. Synthesis of PHEO.</p></sec><sec id="s2_3"><title>2.3. Synthesis of 2-[(2-(Phthalazin-1-yl)Hydrazono)Methyl]Phenol (PHMP)</title><p>A (1.0 mmol, 0.201 g) of hydralazine hydrochloride and sodium acetate (buffering agent) (1.0 mmol, 0.137 g) was dissolved in 15 mL of ethanol and mixed with 0.104 mL of 2-hydroxybenzaldehyde. The solution was transferred into a 100 mL round bottom flask and then refluxed for three hours while stirring at a temperature of about 70˚C to 75˚C and allowed to cool overnight. The yellow precipitate (PHMP) was separated by filtration, washed with ethanol and allowed to air dry (yield = 76.05%). The filtrate was sealed using paraffin in a vial and kept for further crystalization by slow evaporation to improve on the yield. Scheme 2 shows the synthetic route for PHMP.</p><p>IR (KBr, cm<sup>−1</sup>): ν 3400, 3100.1, 1267.9, 1607.4, 960.9. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 500 MHz): 12.11 (s, 1H, OH), 10.30 (s, 1H, N-H), 8.69 (s, 1H, H-1’), 6.90 and 8.33 (benzene hydrogens of the hydralazine moiety) ppm. <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 125 MHz): 157.0 (C-1), 154.0 (C-3’), 147.0 (C-1’) ppm.</p></sec><sec id="s2_4"><title>2.4. Organisms and Growth Conditions</title><p>Microorganisms were obtained from the culture collections of the Antimicrobial and biocontrol Agents Unit at the Department of Biochemistry, University of Yaounde 1, Cameroon. Organisms were as follows: Streptococcus pneumoniae (Klein) Chester, ATCC49619, Staphylococcus aureus BAA 917, Staphylococcus aureus subsp. aureus Rosenbach, ATCC 43300, Staphylococcus aureus NR45003, Staphylococcus aureus NR46003, Staphylococcus aureus CP7625, Shigella flexineri NR518, Salmonella enterica subsp. enterica serovar AnatumNR4294, Salmonella enterica subsp. enterica serovar Muenchen NR4311, Salmonella enterica subsp. enterica, strain A36 is serovar TyphimuriumNR-13555, Pseudomonas aeruginosa NMC592, Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan ATCC 13883, Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan ATCC 700603, Klebsiella pneumonae NR41916, Escherishia coli ATCC25922, Escherishia coli ATCC35218, Enterococcus feacalis ATCC51219, Staphylococcus aureus NR46374, and Hemophyllus influenza ATCC49247. Organisms were maintained on Muller Hinton agar (MHA) (Oxoid). at 37˚C. Inocula were prepared by diluting overnight cultures in saline to 0.5 McFarland, approximately 10<sup>8</sup> cfu·ml<sup>−1</sup>. These suspensions were further diluted with medium as required.</p><disp-formula id="scirp.98707-formula2"><graphic  xlink:href="//html.scirp.org/file/1-1020713x3.png"  xlink:type="simple"/></disp-formula><p>Scheme 2. Synthesis of PHMP.</p>Drug susceptibility Testing Procedure<p>Stock solution preparation</p><p>Stock solution of each sample was prepared at 100 mg/mL in DMSO.</p></sec><sec id="s2_5"><title>2.5. Antimicrobial Assays</title><p>For the estimation of the antimicrobial activities of the plant extracts, a broth dilution method was employed for minimum inhibitory contraction (MIC) following the Clinical and Laboratory Standards Institute (CLSI) guidelines M07-A10. Each compound was tested in duplicate for MIC determination. More specifically, 50 &#181;L of Mueller Hinton broth (MHB) were introduced in a 96-well microplate respectively. 50 &#181;L of compound were added to wells of the first line. A serial twofold dilution was made by transferring 50 &#181;L of the mixture of the first wells to the next one up to the last, final concentrations varying from 250 to 7.81 &#181;g/mL. Then, 50 &#181;L of an inoculum of 1 &#215; 10<sup>6</sup> cells/mL were introduced in all the wells except those of the sterility control. The final concentration of DMSO was &lt;1%. Each plate also contained a positive control, Amoxicillin, a negative control and a blank. Plates were incubated during 24 hours. The lowest concentration of compound that inhibited the visible growth of a microorganism was defined as minimum inhibitory concentration (MIC).</p></sec><sec id="s2_6"><title>2.6. Antioxidant Assay</title><sec id="s2_6_1"><title>2.6.1. Organ Homogenates</title><p>A 2.5 month old male Wistar albino rat of 150 g was obtained from the Biochemistry animal house of the Faculty of Science of the University of Bamenda. They were handled according to ethical guidelines of the Cameroon National Veterinary Laboratory and were given food and water ad libitum. After sacrifice, the liver and testes were excised out, weighed and used to prepare 20% (W/V) homogenates using phosphate buffer (pH 7.4, 50 mM).</p></sec><sec id="s2_6_2"><title>2.6.2. Chemicals</title><p>Ascorbic acid and Thiobarbituric, trichloroacetic acids were gotten from Griffin and George (Wembly Middlesex, England). Methanol was purchased from LobaChemiePvt. Ltd. 107, Woodehouse (Mumbai, India). Other chemicals were of high quality grade.</p></sec><sec id="s2_6_3"><title>2.6.3. Evaluation of the Antioxidant Reducing Power</title><p>The antioxidant reducing power of the synthesized compounds PHEO and PHMP was evaluated using the method as described by Kamtekar and collaborators in 2014 [<xref ref-type="bibr" rid="scirp.98707-ref21">21</xref>]. The standard ascorbic acid or synthesized compounds (50, 100, 150, 200, 250 and 300 &#181;g/mL) was introduced in the tube, then 0.4 mL of phosphate buffer (pH 6.6, 0.2 M) and 0.4 mL of 1% KFe(CN)<sub>6</sub> were successively added. After homogenization, the mixture was incubated at 50˚C for 20 min, then cooled, and centrifuged (3500 rpm, 10 min, 25˚C). To 1 mL of supernatant was added 1 mL of 10% TCA, 1mL of distilled water and 0.2 mL of 0.1% FeCl<sub>3</sub>. After homogenization, the absorbance was measured at 593 nm using a UV-Vis spectrophotometer.</p></sec><sec id="s2_6_4"><title>2.6.4. Inhibition of Lipid Peroxidation</title><p>A volume (0.8 mL) of phosphate buffer (pH 7.4, 50 mM) and 0.1 mL of liver or testis homogenate were added to standard ascorbic acid or synthesized compounds, PHEO and PHMP (50, 100, 150, 200, 250 and 300 &#181;g/mL), followed by 0.1 mL of Fe<sub>2</sub>(SO<sub>4</sub>)<sub>2</sub>. After homogenization, the mixture was incubated at 37˚C for 15 min, then 1 mL of 20% TCA and 1 mL of 0.67% TBA, were added. The mixture was incubated at 90˚C for 10 min, cooled and centrifuged (3000 rpm, 15 min, 4˚C). The supernatant was collected and optical density read at 530 nm [<xref ref-type="bibr" rid="scirp.98707-ref22">22</xref>] and percentage inhibition (%I) of the standard and the synthesized compounds, PHEO and PHMP computed.</p></sec><sec id="s2_6_5"><title>2.6.5. Catalase Activity</title><p>Ascorbic acid or the synthesized compounds, PHEO and PHMP (50, 100, 150, 200, 250 and 300 &#181;g/mL) were introduced into test tubes containing 0.4 mL of 9% H<sub>2</sub>O<sub>2</sub> and 2.3 mL of phosphate buffer (pH 7.2, 0.1 M) and 0.4 mL of the liver or testis homogenate were added. The absorbance was recorded at 240 nm using a UV-Vis spectrophotometer at 30, 60 and 90 seconds. Catalase activity was expressed as IU/mg protein [<xref ref-type="bibr" rid="scirp.98707-ref23">23</xref>].</p></sec><sec id="s2_6_6"><title>2.6.6. Statistical Analyses</title><p>For ferric reducing power and lipid peroxidation, the fifty percent efficient (EC<sub>50</sub>) and inhibitory (IC<sub>50</sub>) concentration of the tested compound were determined. Differences between treatments were assessed by one factor ANOVA followed by the Student-Newman-Keulstest, and P values less than 0.05 were considered statistically significant. All analyses were performed using Graphpad Instat software Version 3.0.</p></sec></sec><sec id="s2_7"><title>2.7. Antiplasmodial Assay</title>SYBR Green I Based Fluorescence Assay<p>Drug sensitivity assay was carried out in 96-well microtitration plates using SYBR green I based fluorescence assay. Sorbitol-synchronized ring stage parasites, Plasmodium falciparum Dd2 (haematocrit: 3%, parasitaemia: 0.5%, 90 μl) under normal culture conditions were incubated in the presence of prediluted extracts and reference drug. The final concentration in the test plate was range from 0.781 to 100 μg/mL for extract and 0.0078 to 1 &#181;M for artemisinin and chloroquine, in the total volume of 100 &#181;L of culture. After 72 h of incubation, SYBR Green I was added and the fluorescence was measured using a Fluoroskan Ascent multi-well plate reader with excitation and emission at 485 and 538 nm, respectively. The fluorescence counts were plotted against the logarithm of sample concentration and the 50% inhibitory concentration (IC<sub>50</sub>) was determined by analysis of dose–response curves using GraphPad Prism 5. Experiments were done in duplicate. Cut off point for antiplasmodial activity of synthesized compounds is as follows: Highly active (IC<sub>50</sub> ≤ 5 μg/mL), promisingly active (5 &lt; IC<sub>50</sub> ≤ 10 μg/mL), good activity 10 &lt; IC<sub>50</sub> ≤ 20 μg/mL, moderately active (20 &lt; IC<sub>50</sub> ≤ 40 μg/mL), marginally active (40 &lt; IC<sub>50</sub> ≤ 70 μg/mL), poorly active (70 &lt; IC<sub>50</sub> ≤ 100 μg/mL) [<xref ref-type="bibr" rid="scirp.98707-ref24">24</xref>].</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><p>The condensation reaction between hydralazine hydrochloride and 4-acetylmorpholine afforded PHEO (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and that between hydralazine hydrochloride and 2-hydroxybenzaldehyde afforded PHMP (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><sec id="s3_1"><title>3.1. Infrared Spectra</title><p>The IR spectrum of the PHMP (<xref ref-type="fig" rid="fig3">Figure 3</xref>) recorded in the 4000 - 400 cm<sup>−1</sup> region displayed strong bands at 3400 cm<sup>−1</sup> and 3100.1 cm<sup>−1</sup> corresponding to the O-H and the N-H stretching vibrations respectively [<xref ref-type="bibr" rid="scirp.98707-ref25">25</xref>]. A sharp band was seen at</p><p>1267.9 cm<sup>−1</sup> corresponding to the C-O stretch. Other strong bands were observed at 1607.4 cm<sup>−1</sup> corresponding to the C=N stretch [<xref ref-type="bibr" rid="scirp.98707-ref26">26</xref>] and at 960.9 cm<sup>−1</sup> attributed to the N-N stretch. This brought in to evidence the presence of these functional groups in PHMP.</p><p>The IR spectrum of the PHEO (<xref ref-type="fig" rid="fig4">Figure 4</xref>) recorded in the 4000 - 400 cm<sup>−1</sup> region showed a band at 3862 cm<sup>−1</sup> for the residual H<sub>2</sub>O molecule [<xref ref-type="bibr" rid="scirp.98707-ref25">25</xref>]. Also, sharp bands at 3501 cm<sup>−1</sup> and 1664 cm<sup>−1</sup> corresponding to the N-H stretch and the azomethine C=N respectively. Other sharp bands were observed at 1271 cm<sup>−1</sup> and 970 cm<sup>−1</sup> attributed to the C-O stretch and N-N stretch respectively. The band observed at 1611 cm<sup>−1</sup> was that of the C=N stretch [<xref ref-type="bibr" rid="scirp.98707-ref26">26</xref>]. The very intense band at 1611 cm<sup>−1</sup> is attributed to the C=C vibration [<xref ref-type="bibr" rid="scirp.98707-ref25">25</xref>].</p></sec><sec id="s3_2"><title>3.2. <sup>1</sup>H NMR Spectra</title><p>The proton NMR spectrum of PHMP (<xref ref-type="fig" rid="fig5">Figure 5</xref>) was recorded in deuterated DMSO as the solvent. The signal at 12.11 ppm (1H, s) is attributed to the O-H while that at 10.30 ppm (1H, s) is attributed to the N-H and is highly deshielded because of its tautomeric nature. A signal observed at 8.69 ppm (1H, s) was attributed to the methyne (-N=C-H) proton at carbon 1’. The group of signals between 6.90 ppm and 8.33 ppm has been attributed to the benzene protons of the hydralazine moiety. <xref ref-type="fig" rid="fig5">Figure 5</xref> shows the <sup>1</sup>H NMR spectrum of the PHMP.</p><p>The proton NMR spectrum of PHEO (<xref ref-type="fig" rid="fig6">Figure 6</xref>) was recorded in deuterated methanol (CD<sub>3</sub>OD) as the solvent. The signal at 8.85 ppm (1H, s) is attributed to the N-H of the hydralazine; deshielded because of its tautomeric nature, while that at 8.10 ppm (1H, dd) is attributed to the C-H of the benzene ring. The signal at 2.45 ppm (3H, s) is attributed to the methyl group while those at 2.29 ppm (4H, t) and 2.60 ppm (4H, t) are attributed to the two groups of methylene protons of the morpholine moiety. <xref ref-type="fig" rid="fig6">Figure 6</xref> shows the <sup>1</sup>H NMR spectrum of the PHEO.</p><p>The <sup>13</sup>C NMR spectrum of PHMP (<xref ref-type="fig" rid="fig7">Figure 7</xref>) was recorded in deuterated DMSO as the solvent. It displayed 15 signals between 116.0 ppm and 157.0 ppm. The signals at 157.0, 154.0 and 147.0 were respectively attributed to carbons 1, 3’ and 1’.</p><p>The <sup>13</sup>C NMR spectrum of PHEO (<xref ref-type="fig" rid="fig8">Figure 8</xref>) was recorded in deuterated DMSO as the solvent. The signals at 151.6, 135.9 and 134.2 were respectively assigned to carbons 1’, 1 and 4.</p></sec><sec id="s3_3"><title>3.3. Anti-Plasmodial Activity</title><p>PHEO and PHMP were tested for anti-plasmodial activity using the SYBR green I based fluorescence assay and the results are presented in <xref ref-type="table" rid="table1">Table 1</xref>. PHEO inhibited the growth of the malaria parasites with a percentage inhibition of 78.55%, lower than the 80.41% obtained with the standard treatment of malaria, Artemisinin. Likewise, PHMP inhibited the growth of the malaria parasites with a percentage inhibition of 78.06%, lower than the 80.41% obtained with the standard treatment of malaria, Artemisinin. Considering that their percentage inhibitions in the preliminary assay were less than 80%, PHEO and PHMP were not considered for the Dose-Response studies.</p></sec><sec id="s3_4"><title>3.4. Antimicrobial Activity</title><p>Antibacterial activities of PHEO and PHMP are recorded in <xref ref-type="table" rid="table2">Table 2</xref>. PHEO showed low activity only on one bacterial strain with MIC value of 250 &#181;g/ml against Hemophyllus influenza ATCC49247. Antimicrobial activity of a compound is very interesting if the MIC is below 10 &#181;g/ml, interesting or moderate if 10 &lt; MIC &#163; 100 &#181;g/ml and low if MIC &gt; 100 &#181;g/ml [<xref ref-type="bibr" rid="scirp.98707-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.98707-ref27">27</xref>]. Based on above-mentioned criteria, PHEO had low antimicrobial activity. PHMP was effective (interesting activity) against 4 bacterial strains out of 19 with MIC of 31.25 - 250 &#181;g/ml against Hemophyllus influenza ATCC49247; Staphylococcus aureus NR46374; Staphylococcus aureus BAA 917 and Streptococcus pneumoniae</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Antiplasmodial activity of synthetic compounds</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compound</th><th align="center" valign="middle" >% Inhibition</th><th align="center" valign="middle" >IC<sub>50</sub> (μg/mL)</th></tr></thead><tr><td align="center" valign="middle" >PHEO</td><td align="center" valign="middle" >78.55</td><td align="center" valign="middle" >N.D.</td></tr><tr><td align="center" valign="middle" >PHMP</td><td align="center" valign="middle" >78.06</td><td align="center" valign="middle" >N.D.</td></tr><tr><td align="center" valign="middle" >ART</td><td align="center" valign="middle" >80.41</td><td align="center" valign="middle" >18.18 nM</td></tr><tr><td align="center" valign="middle" >CQ</td><td align="center" valign="middle" >N.D.</td><td align="center" valign="middle" >449.3 nM</td></tr></tbody></table></table-wrap><p>ART = artemisinine; CQ = chloroquine; N.D. = Not determined.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Antibacterial activities of PHEO and PHMP</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="4"  >Antimicrobial activity (MIC in &#181;g/mL)</th></tr></thead><tr><td align="center" valign="middle" >Bacterial strains, Synthetic compounds</td><td align="center" valign="middle" >PHEO</td><td align="center" valign="middle" >PHMP</td><td align="center" valign="middle" >Amoxicilin</td></tr><tr><td align="center" valign="middle" >Streptococcus pneumoniae (Klein) Chester, ATCC49619</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >250</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus BAA 917;</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus subsp. aureus Rosenbach, ATCC 43300</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;64</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus NR45003</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;64</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus NR46003</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;64</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus CP7625</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Shigellaflexineri NR518</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Salmonella enterica subsp. enterica serovar Anatum, NR4294</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >16</td></tr><tr><td align="center" valign="middle" >Salmonella enterica subsp. enterica serovar Muenchen, NR4311</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Salmonella enterica subsp. enterica, strain A36 is serovar Typhimurium, NR-13555</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >64</td></tr><tr><td align="center" valign="middle" >Pseudomonas aeruginosa NMC592</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan ATCC 13883</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Klebsiellapneumoniaesubsp. pneumoniae (Schroeter) Trevisan ATCC 700603</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >KlebsiellapneumonaeNR41916</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Escherishia coli ATCC25922</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Escherishia coli ATCC35218</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;</td></tr><tr><td align="center" valign="middle" >Enterococcus feacalis ATCC51219</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Staphylococcus aureus NR46374</td><td align="center" valign="middle" >&gt;250</td><td align="center" valign="middle" >31.25</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Hemophyllus influenza ATCC49247</td><td align="center" valign="middle" >250</td><td align="center" valign="middle" >31.25</td><td align="center" valign="middle" >0.5</td></tr></tbody></table></table-wrap><p>(Klein) Chester ATCC49619. However, the results achieved can serve as starting point for lead optimisation in order to generate more active lead compounds that can be developed into new antibacterial drugs.</p></sec><sec id="s3_5"><title>3.5. Antioxidant Activity</title><sec id="s3_5_1"><title>3.5.1. Ferric Reducing Powder and Lipid Peroxidation</title><p>The effects of different compounds and vitamin C on reduction of ferric ions and peroxidation of lipids are presented in <xref ref-type="table" rid="table3">Table 3</xref>. In general PHEO and PHMP showed higher reducing activity on ferric ions than the reference compound vitamin C. On lipid peroxidation, PHEO showed higher inhibition (P &lt; 0.05) while PHMP showed lower inhibition (P &lt; 0.05) compared to vitamin C.</p></sec><sec id="s3_5_2"><title>3.5.2. Catalase Activity</title><p>The catalase activity in the presence of PHEO, PHMP and Vitamin C is depicted in <xref ref-type="fig" rid="fig9">Figure 9</xref>. Catalase activity showed concentration dependent effect in the presence of all compound. In general Vit C presented higher stimulatory effect on the enzyme activity than PHEO and PHMP. PHMP showed a lower effect on catalase activity.</p></sec></sec></sec><sec id="s4"><title>4. Conclusions</title><p>PHEO and PHMP were synthesized from hydralazine hydrochloride and characterized by spectroscopic methods.</p><p>PHEO showed low anti-microbial activity only on one bacterial strain with MIC value of 250 &#181;g/ml against Hemophyllus influenza ATCC49247. PHMP showed interesting activity against 4 bacterial strains out of 19 with MIC of 31.25 - 250 &#181;g/ml against Hemophyllus influenza ATCC49247; Staphylococcus aureus NR46374; Staphylococcus aureus BAA 917 and Streptococcus pneumoniae (Klein) Chester ATCC49619.</p><p>For antioxidant activity, PHEO and PHMP showed higher reducing activity on ferric ions than the reference compound Vit C and on lipid peroxidation,</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Effects of compounds and Vit C on reduction of ferric ions and peroxidation of lipids</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle" >Ferric reducing power</th><th align="center" valign="middle" >Lipid peroxidation</th></tr></thead><tr><td align="center" valign="middle" >EC<sub>50</sub> (&#181;g/mL)</td><td align="center" valign="middle" >IC<sub>50</sub> (&#181;g/mL)</td></tr><tr><td align="center" valign="middle" >Vit C</td><td align="center" valign="middle" >1.749 &#177; 0.001</td><td align="center" valign="middle" >1.45 &#177; 0.01</td></tr><tr><td align="center" valign="middle" >PHEO</td><td align="center" valign="middle" >1.348 &#177; 0.047*</td><td align="center" valign="middle" >1.03 &#177; 0.32*</td></tr><tr><td align="center" valign="middle" >PHMP</td><td align="center" valign="middle" >1.368 &#177; 0.105*</td><td align="center" valign="middle" >2.59 &#177; 0.19*</td></tr></tbody></table></table-wrap><p>*P &lt; 0.05 compared to the reference Vit C, Student-Newman-Keuls test.</p><p>PHEO and PHMP showed higher inhibition than Vit C. Catalase activity showed concentration dependent effect in the presence of all compounds. In general, Vit C presented higher stimulatory effect on the enzyme activity than PHEO and PHMP. PHMP showed a lower effect on catalase activity.</p><p>PHEO and PHMP inhibited the growth of the malaria parasites with percentage inhibitions of 78.55% and 78.06% respectively; lower than the 80.41% obtained with the standard treatment of malaria, Artemisinin. Considering that their percentage inhibitions in the preliminary assay were less than 80%, PHEO and PHMP were not considered for the Dose-Response studies.</p><p>The anti-microbial, anti-oxidant and anti-plasmodial activities of these compounds are reported for the first time and the results indicate that these novel ligands can be exploited as anti-microbial and anti-oxidant agents.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We are grateful to the Department of Chemistry, University of Buea for providing the necessary support to perform the experiments.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Awantu, A.F., Fongang, Y.S.F., Ayimele, G.A., Nantia, E.A., Fokou, P.V.T., Boyom, F.F., Ngwang, C.K., Lenta, B.N. and Ngouela, S.A. (2020) Novel Hydralazine Schiff Base Derivatives and Their Antimicrobial, Antioxidant and Antiplasmodial Properties. International Journal of Organic Chemistry, 10, 1-16. https://doi.org/10.4236/ijoc.2020.101001</p></sec></body><back><ref-list><title>References</title><ref id="scirp.98707-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sathe, B.S., Jaychandran, E., Jagtap, V.A. and Sreenivasa, G.M. (2011) Synthesis Characterization and Anti-Inflammatory Evaluation of New Fluorobenzothiazole Schiff’s Bases. International Journal of Pharmaceutical Research and Development, 3, 164-169. https://doi.org/10.1155/2013/893512</mixed-citation></ref><ref id="scirp.98707-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sondhi, S.M., Singh, N., Kumar, A., Lozach, O. and Meijer, L. (2006) Synthesis, Anti-Inflammatory, Analgesic and Kinase (CDK-1, CDK-5 and GSK-3) Inhibition Activity Evaluation of Benzimidazole/Benzoxazole Derivatives and Some Schiff’s Bases. Bioorganic and Medicinal Chemistry, 14, 3758-3765. https://doi.org/10.1016/j.bmc.2006.01.054</mixed-citation></ref><ref id="scirp.98707-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pandey, A., Dewangan, D., Verma, S., Mishra, A. and Dubey, R.D. (2011) Synthesis of Schiff Bases of 2-Amino-5-aryl-1,3,4-thiadiazole and Its Analgesic, Anti-Inflammatory, Anti-Bacterial and Anti-Tubercular Activity. International Journal of ChemTech Research, 3, 178-184. https://doi.org/10.1155/2012/145028</mixed-citation></ref><ref id="scirp.98707-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chandramouli, C., Shivanand, M.R., Nayanbhai, T.B., Bheemachari, B. and Udupi, R.H. (2012) Synthesis and Biological Screening of Certain New Triazole Schiff Bases and Their Derivatives Bearing Substituted Benzothiazole Moiety. Journal of Chemical and Pharmaceutical Research, 4, 1151-1159.</mixed-citation></ref><ref id="scirp.98707-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chinnasamy, R.P., Sundararajan, R. and Govindaraj, S. (2010) Synthesis, Characterization, and Analgesic Activity of Novel Schiff Base of Isatin Derivatives. Journal of Advanced Pharmaceutical Technology and Research, 1, 342-347. https://doi.org/10.4103/0110-5558.72428</mixed-citation></ref><ref id="scirp.98707-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Venkatesh, P. (2011) Synthesis, Characterization and Antimicrobial Activity of Various Schiff Bases Complexes of Zn(II) and Cu(II) Ions. Asian Journal of Pharmaceutical and Health Sciences, 1, 8-11. https://doi.org/10.1016/j.rechem.2019.100006</mixed-citation></ref><ref id="scirp.98707-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chaubey, A.K. and Pandeya, S.N. (2012) Synthesis &amp; Anticonvulsant Activity (Chemo Shock) of Schiff and Mannich Bases of Isatin Derivatives with 2-Amino Pyridine (Mechanism of Action). International Journal of PharmTech Research, 4, 590-598. https://doi.org/10.11648/j.ajhc.20190502.12</mixed-citation></ref><ref id="scirp.98707-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Miri, R., Razzaghi-asl, N. and Mohammadi, M.K. (2013) QM Study and Conformational Analysis of an Isatin Schiff Base as a Potential Cytotoxic Agent. Journal of Molecular Modeling, 19, 727-735. https://doi.org/10.1007/s00894-012-1586-x</mixed-citation></ref><ref id="scirp.98707-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Avaji, P.G., Vinod Kumar, C.H., Patil, S.A., Shivananda, K.N. and Nagaraju, C. (2009) Synthesis, Spectral Characterization, In-Vitro Microbiological Evaluation and Cytotoxic Activities of Novel Macrocyclic Bishydrazone. European Journal of Medicinal Chemistry, 44, 3552-3559. https://doi.org/10.1016/j.ejmech.2009.03.032</mixed-citation></ref><ref id="scirp.98707-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Venugopala, K.N. and Jayashree, B.S. (2003) Synthesis of Carboxamides of 2’-amino-4’-(6-bromo-3-coumarinyl) Thiazole as Analgesic and Antiinflammatory Agents. Indian Journal of Heterocyclic Chemistry, 12, 307-310.</mixed-citation></ref><ref id="scirp.98707-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Mounika, K., Anupama, B., Pragathi, J. and Gyanakumari, C. (2010) Synthesis, Characterization and Biological Activity of a Schiff Base Derived from 3-Ethoxy Salicylaldehyde and 2-Amino Benzoic Acid and Its Transition Metal Complexes. Journal of Scientific Research, 2, 513-524. https://doi.org/10.3329/jsr.v2i3.4899</mixed-citation></ref><ref id="scirp.98707-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Aboul-Fadl, T., Mohammed, F.A. and Hassan, E.A. (2003) Synthesis, Antitubercular Activity and Pharmacokinetic Studies of Some Schiff Bases Derived from 1-Alkylisatin and Isonicotinic Acid Hydrazide (INH). Archives of Pharmacal Research, 26, 778-784. https://doi.org/10.1007/BF02980020</mixed-citation></ref><ref id="scirp.98707-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chohan, Z.H., Praveen, M. and Ghaffar, A. (1997) Structural and Biological Behaviour of Co(II), Cu(II) and Ni(II) Metal Complexes of Some Amino Acid Derived Schiff-Bases. Metal-Based Drugs, 4, 267-272. https://doi.org/10.1155/MBD.1997.267</mixed-citation></ref><ref id="scirp.98707-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Knobler, S.L., Lemon, S.M., Najafi, M. and Burroughs, T. (2003) The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. National Academies Press (US), Washington DC.</mixed-citation></ref><ref id="scirp.98707-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Piddock, L.J.V. (2017) Understanding Drug Resistance Will Improve the Treatment of Bacterial Infections. Nature Reviews Microbiology, 15, 639. https://doi.org/10.1038/nrmicro.2017.121</mixed-citation></ref><ref id="scirp.98707-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kuete, V. (2010) Potential of Cameroonian Plants and Derived Products against Microbial Infections: A Review. Planta Medica, 76, 1479-1491. https://doi.org/10.1055/s-0030-1250027</mixed-citation></ref><ref id="scirp.98707-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Frith, K.A., Fogel, R., Goldring, J.P.D., Krause, R.G.E., Khati, M., Hoppe, H. and Limson, J.L. (2018) Towards Development of Aptamers That Specifically Bind to Lactate Dehydrogenase of Plasmodium falciparum through Epitopic Targeting. Malaria Journal, 17, 191. https://doi.org/10.1186/s12936-018-2336-z</mixed-citation></ref><ref id="scirp.98707-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yeung, S. (2018) Malaria—Update on Antimalarial Resistance and Treatment Approaches. The Pediatric Infectious Disease Journal, 37, 367-369. https://doi.org/10.1097/INF.0000000000001887</mixed-citation></ref><ref id="scirp.98707-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gülcin, I., Oktay, M., Kirecci, E. and Küfreviolu, I. (2003) Screening of Antioxidant and Antimicrobial Activities of Anise (Pimpellaanisum L.) Seed Extracts. Food Chemistry, 83, 371-382. https://doi.org/10.4103/epj.epj_44_18</mixed-citation></ref><ref id="scirp.98707-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yoshikawa, T. and Naito, Y. (2002) What Is Oxidative Stress? JMAJ, 45, 271-276.</mixed-citation></ref><ref id="scirp.98707-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Arnous, A., Makris, D.P. and Kefalas, P. (2001) Effect of Principal Polyphenolic Components in Relation to Antioxidant Characteristics of Aged Red Wines. Journal of Agriculture and Food Chemistry, 49, 5736-5742. https://doi.org/10.1021/jf010827s</mixed-citation></ref><ref id="scirp.98707-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kamtekar, S., Keer, V. and Patil, V. (2014) Estimation of Phenolic Content, Flavonoid Content, Antioxidant and Alpha Amylase Inhibitory Activity of Marketed Polyherbal Formulation. Journal of Applied Pharmaceutical Sciences, 4, 61-65.</mixed-citation></ref><ref id="scirp.98707-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Nilsson, U.A., Olsson, L.I., Carlin, G. and Bylund-Fellenius, A.C. (1989) Inhibition of Lipid Peroxidation by Spin Labels. Journal of Biological Chemistry, 264, 11131-11135.</mixed-citation></ref><ref id="scirp.98707-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Misra, H.P. and Fridovich, I. (1972) The Generation of Superoxide Radical during the Autoxidation of Hemoglobin. Journal of Biological Chemistry, 247, 6960-6962.</mixed-citation></ref><ref id="scirp.98707-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yong, J.N., Majoumo-Mbe, F., Samje, M. and Nfor, E.N. (2016) Synthesis, Molecular Structure and Anti-Onchocercal Studies of 1-(Phthalazin-1-(2H)-one)[(Pyridin- 2-yl)ethylidene]hydrazone. International Journal of Organic Chemistry, 6, 77-84. https://doi.org/10.4236/ijoc.2016.61008</mixed-citation></ref><ref id="scirp.98707-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Nfor, E.N., Husian, A., Majoumo-Mbe, F., Njah, N.N., Offiong, E.O. and Bourne, S.A. (2013) Synthesis, Crystal Structure and Antifungal Activity of Ni(II) Complex of a New Hydrazine Derived from Antihypertensive Drug Hydralazine Hydrochloride. Polyhedron, 63, 213-217. https://doi.org/10.1016/j.poly.2013.07.028</mixed-citation></ref><ref id="scirp.98707-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Singh, N., Kaushik, N.K., Mohanakrishnan, D., Tiwari, S.K. and Sahal, D. (2015) Antiplasmodial Activity of Medicinal Plants from Chhotanagpur Plateau, Jharkhand, India. Journal of Ethnopharmacology, 165, 152-162. https://doi.org/10.1016/j.jep.2015.02.038</mixed-citation></ref></ref-list></back></article>